AMGEN's Denosumab Shows Great Results
July 7, 2009Web posted by PAF
--
DENOSUMAB DEMONSTRATES SUPERIORITY OVER ZOMETA® IN PIVOTAL PHASE 3 HEAD-TO-HEAD TRIAL IN BREAST CANCER PATIENTS WITH BONE METASTASES
Denosumab Significantly Delayed the Time to the First Skeletal Related Event and Significantly Reduced First and Subsequent Skeletal Related Events Compared to Zometa
First of Three Pivotal Oncology Trials Comparing Denosumab to Zometa in the Advanced Cancer Setting Meets Primary and Secondary Endpoints
View the Complete Press Release
